Lv5
1190 积分 2022-06-07 加入
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response
1个月前
已完结
KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress
1个月前
已完结
TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models
1个月前
已完结
RSK inhibitors as potential anticancer agents: Discovery, optimization, and challenges
1个月前
已完结
The Moderna cancer vaccine offers hope — now we must speed up personalized therapies
1个月前
已完结
In vivo chimeric antigen receptor (CAR)-T cell therapy
1个月前
已完结
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
1个月前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
1个月前
已完结
Discovery of 2-Aminopyrimidine Derivatives as Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced hERG Inhibitory Activities
2个月前
已完结
Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor
2个月前
已完结
皖公网安备34019202002308
